, /PRNewswire/ -- Ulcerative colitis is an idiopathic inflammatory bowel disease affecting ~1.5 million patients in the US and with an unknown exact cause. It affects the colonic mucosa and is clinically characterized by diarrhea, stomach discomfort, pain, and hematochezia.
The disease's extent varies, affecting either the rectum, the splenic flexure of the left side of the colon, or the whole of the rectum and bowel. As per DelveInsight analysis, the total ulcerative colitis diagnosed prevalent cases in the 7MM comprised approximately cases in 2023 and are projected to increase by 2034. Per analyst estimates, approximately of cases accounted for moderate to severe cases of ulcerative colitis among the 7MM.
The current treatments for ulcerative colitis depend on the severity of the disease and are broadly divided into six classes, comprising . The emergence of several mechanisms of action, like , and others will be expanding the treatment landscape of ulcerative colitis. There have been significant advancements in treating ulcerative colitis over the years.
However, safety remains a major challenge. The lack of a safer and curative treatment option severely impacts patients' quality of life and daily activities. While current treatments are effective for some patients with ulcerative colitis, others need multiple lines of therapy, indicating a need for alternative treatments to achieve disease control.
Several major pharmaceutical companies are collaborating to develop new so.
